M. Waelbroeck

发表

Evidence for a direct interaction between the Thr 11 residue of vasoactive intestinal polypeptide and Tyr 184 located in the first extracellular loop of the

P. Robberecht, P. Vertongen, Ingrid Nachtergael, 2003 .

Two tyrosine residues in the first transmembrane helix of the human vasoactive intestinal peptide receptors play a role in supporting the active conformation

P. Robberecht, P. Vertongen, I. Langer, 2002, British journal of pharmacology.

VPAC(1) receptors have different agonist efficacy profiles on membrane and intact cells.

F. Grégoire, P. de Neef, P. Robberecht, 2002, Cellular signalling.

Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC2: role of basic residues in the second transmembrane helix

P. Robberecht, P. Vertongen, I. Langer, 2001, British journal of pharmacology.

Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts.

J. Goossens, P. de Neef, P. Robberecht, 1994, Biochemical and biophysical research communications.

The Long-Acting Vasoactive Intestinal Polypeptide Agonist RO 25-1553 Is Highly Selective of the VIP2 Receptor Subclass

P. Robberecht, A. Vandermeers, M. Vandermeers-piret, 1997, Peptides.

Development of High Affinity Selective VIP1 Receptor Agonists

P. Robberecht, A. Vandermeers, J. Rathé, 1997, Peptides.

In Vitro Properties of a High Affinity Selective Antagonist of the VIP1 Receptor

P. Robberecht, M. Waelbroeck, J. Cnudde, 1997, Peptides.

Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation.

P. de Neef, P. Robberecht, M. Waelbroeck, 1999, European journal of biochemistry.

Allosteric Drugs Acting at Muscarinic Acetylcholine Receptors

M. Waelbroeck, 2003, Neurochemical Research.

Analogues of VIP, Helodermin, and PACAP Discriminate between Rat and Human VIP1 and VIP2 Receptors a

P. Robberecht, A. Vandermeers, M. Waelbroeck, 1998, Annals of the New York Academy of Sciences.

Affinity profiles of hexahydro-sila-difenidol analogues at muscarinic receptor subtypes.

H. Boddeke, J. Christophe, C. Strohmann, 1989, European journal of pharmacology.

Vasoactive intestinal peptide (VIP) stimulates [Ca2+]iand cyclic AMPin CHO cells expressing Gα16

P. Robberecht, P. Vertongen, I. Langer, 2001 .

Techniques: promiscuous Galpha proteins in basic research and drug discovery.

Graeme Milligan, Evi Kostenis, G. Milligan, 2005, Trends in pharmacological sciences.

Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC2 receptor

P. Robberecht, M. Waelbroeck, J. Cnudde, 2000, Peptides.

Evidence that the lizard helospectin peptides are O-glycosylated.

P. Robberecht, A. Vandermeers, M. Vandermeers-piret, 2000, European journal of biochemistry.

Role of charged amino acids conserved in the vasoactive intestinal polypeptide/secretin family of receptors on the secretin receptor functionality☆

J. Vilardaga, P. Robberecht, N. Moguilevsky, 1999, Peptides.

Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites.

C. Delporte, C. De Vriese, F. Grégoire, 2004, Endocrinology.

A comparison between muscarinic receptor occupancy, adenylate cyclase inhibition, and inotropic response in human heart

P. Robberecht, M. Delhaye, J. Christophe, 1984, Naunyn-Schmiedeberg's Archives of Pharmacology.

Thermodynamics of antagonist binding to rat muscarinic M2 receptors: antimuscarinics of the pridinol, sila‐pridinol, diphenidol and sila‐diphenidol type

J. Christophe, E. Mutschler, R. Tacke, 1993, British journal of pharmacology.

80% of muscarinic receptors expressed by the NB‐OK 1 human neuroblastoma cell line show high affinity for pirenzepine and are comparable to rat hippocampus M1 receptors

J. Christophe, M. Waelbroeck, M. Tastenoy, 1988, FEBS letters.

Uncoupling between beta-adrenoceptors and adenylate cyclase in dog ischemic myocardium

P. Robberecht, J. Christophe, P. Schoenfeld, 1985, Naunyn-Schmiedeberg's Archives of Pharmacology.

The human heart beta-adrenergic receptors. I. Heterogeneity of the binding sites: presence of 50% beta 1- and 50% beta 2-adrenergic receptors.

P. de Neef, P. Robberecht, M. Delhaye, 1983, Molecular pharmacology.

The human heart beta-adrenergic receptors. II. Coupling of beta 2-adrenergic receptors with the adenylate cyclase system.

P. Robberecht, M. Delhaye, J. Christophe, 1983, Molecular pharmacology.

Interaction of Gila monster venom with secretin receptors in rat pancreatic membranes

W. König, L. Gillet, P. Robberecht, 1984, Peptides.

Heart receptors for VIP, PHI and secretin are able to activate adenylate cyclase and to mediate inotropic and chronotropic effects. Species variations and physiopathology

P. Robberecht, J. Christophe, P. Chatelain, 1984, Peptides.

Stereoselective inhibition of muscarinic receptor subtypes by the enantiomers of hexahydro‐difenidol and acetylenic analogues

J. Christophe, C. Strohmann, E. Mutschler, 1990, British journal of pharmacology.

The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins.

C. Delporte, P. Robberecht, J. Winand, 1997, Biochimica et biophysica acta.

The in vitro chronotropic and inotropic effects of vasoactive intestinal peptide (VIP) on the atria and ventricular papillary muscle from Cynomolgus monkey heart

P. Robberecht, J. Christophe, P. Chatelain, 1984, Regulatory Peptides.

Effects of PHI on vasoactive intestinal peptide receptors and adenylate cyclase activity in lung membranes. A comparison in man, rat, mouse and guinea pig

P. Robberecht, M. Delhaye, J. Christophe, 1982, Regulatory Peptides.

Presence of vasoactive intestinal peptide receptors coupled to adenylate cyclase in rat lung membranes.

P. de Neef, P. Robberecht, J. Christophe, 1981, Biochimica et biophysica acta.

Characterization and regulation of the expression of scyllatoxin (Leiurotoxin I) receptors in the human neuroblastoma cell line NB‐OK 1

J. Christophe, M. Waelbroeck, M. Tastenoy, 1991, FEBS letters.

Pharmacological characterization of VIP receptors in human lung membranes

P. Robberecht, J. Christophe, M. Waelbroeck, 1988, Peptides.

Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes.

D. Coy, M. Heiman, P. de Neef, 1985, Endocrinology.

Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.

D. Coy, P. de Neef, P. Robberecht, 1985, Endocrinology.

Vasoactive Intestinal Peptide (VIP) and peptide having N-terminal histidine and C-terminal isoleucine amide (PHI) stimulate adenylate cyclase activity in human heart membranes

P. Robberecht, M. Delhaye, J. Christophe, 1982, Peptides.

Stereoselective interaction of p-fluoro-trihexyphenidyl and its methiodide with four muscarinic receptor subtypes

E. Mutschler, G. Lambrecht, M. Waelbroeck, 1997 .

Influence of monovalent cations on the binding of a charged and an uncharged (‘carbo’‐)muscarinic antagonist to muscarinic receptors

J. Wess, H. Timmerman, E. Mutschler, 1996, British journal of pharmacology.

Functional characterization of muscarinic receptors in rat duodenum

E. Mutschler, G. Lambrecht, M. Waelbroeck, 1995 .

Binding and functional properties of hexocyclium and sila‐hexocyclium derivatives to muscarinic receptor subtypes

C. Strohmann, E. Mutschler, R. Tacke, 1994, British journal of pharmacology.

New functionally selective muscarinic agonists.

J. Christophe, E. Mutschler, U. Moser, 1993, Life sciences.

Synthesis and affinity studies of himbacine derived muscarinic receptor antagonists.

M. Milanesio, Ling-Jie Gao, D. Viterbo, 2002, Bioorganic & medicinal chemistry letters.

Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.

P. de Neef, P. Robberecht, M. Waelbroeck, 1999, Molecular pharmacology.

Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.

P. de Neef, P. Robberecht, M. Waelbroeck, 1996, Molecular pharmacology.

Rat cardiac muscarinic receptors. I. Effects of guanine nucleotides on high- and low-affinity binding sites.

P. Robberecht, J. Christophe, P. Chatelain, 1982, Molecular pharmacology.

Evidence that helodermin, a newly extracted peptide from Gila monster venom, is a member of the secretin/VIP/PHI family of peptides with an original pattern of biological properties

P. Robberecht, A. Vandermeers, M. Vandermeers-piret, 1984, FEBS letters.

Increased number of high-affinity muscarinic receptors in rat heart after phenylhydrazine treatment.

P. de Neef, P. Robberecht, J. Christophe, 1983, European journal of pharmacology.

Effector mechanisms of peptides of the VIP family

P. Robberecht, A. Vandermeers, M. Vandermeers-piret, 1986, Peptides.

Propylbenzilylcholine mustard is selective for rat heart muscarinic receptors having a low affinity for agonists

P. Robberecht, J. Christophe, M. Waelbroeck, 1986, British journal of pharmacology.

mustard isselective forratheart muscarinic receptors having alowaffinity foragonists

P. Robberecht, M. Waelbroeck, P. Deneef, 1986 .

THE STRUCTURAL BASIS OF INSULIN-RECEPTOR BINDING AND COOPERATIVE INTERACTIONS

M. Waelbroeck, P. D. Meyts, 1978 .

Secretin-induced changes in rate, contractility and adenylate cyclase activity in rat heart atria

P. Robberecht, J. Christophe, J. Fontaine, 1984, Pflügers Archiv.

Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.

J. Vilardaga, P. de Neef, P. Robberecht, 1995, European journal of pharmacology.

Activation of guanosine 5'-[gamma-(35)S]thio-triphosphate binding through M(1) muscarinic receptors in transfected Chinese Hamster ovary cell membranes: 2. Testing the "two-states" model of receptor activation.

M. Waelbroeck, 2001, Molecular pharmacology.

Stereoselective interaction of uncharged esters at four muscarinic receptor subtypes.

H. Timmerman, E. Mutschler, G. Lambrecht, 1996, European journal of pharmacology.

The (S)-(+)-enantiomer of dimethindene: a novel M2-selective muscarinic receptor antagonist.

E. Mutschler, U. Moser, G. Lambrecht, 1995, European journal of pharmacology.

Does a radiolabelled ligand bind to a homogeneous population of non-interacting receptor sites?

S. Swillens, P. Champeil, M. Waelbroeck, 1995, Trends in pharmacological sciences.

Binding kinetics of quinuclidinyl benzilate and methyl-quinuclidinyl benzilate enantiomers at neuronal (M1), cardiac (M2), and pancreatic (M3) muscarinic receptors.

J. Christophe, M. Waelbroeck, M. Tastenoy, 1991, Molecular pharmacology.

Two Basic Residues of the h-VPAC1 Receptor Second Transmembrane Helix Are Essential for Ligand Binding and Signal Transduction*

P. Robberecht, P. Vertongen, I. Langer, 2001, The Journal of Biological Chemistry.

Mutations of aromatic residues in the first transmembrane helix impair signalling by the secretin receptor.

P. de Neef, P. Robberecht, E. Di Paolo, 1999, Receptors & channels.

Effects of full and partial beta-adrenergic agonists and antagonists on human lung adenylate cyclase.

P. Robberecht, M. Delhaye, J. Christophe, 1983, Biochemical pharmacology.

Functional Structure of the Secretin Receptor

P. Robberecht, N. Moguilevsky, M. Waelbroeck, 2001 .

Interaction of amino acid residues at positions 8-15 of secretin with the N-terminal domain of the secretin receptor.

J. Vilardaga, P. de Neef, P. Robberecht, 1996, European journal of biochemistry.

Cholinergic and α-Adrenergic Stimulation of Prostaglandin Release by Dog Thyroid in Vitro*

J. Dumont, J. Boeynaems, M. Waelbroeck, 1979 .

Comparative effects of α-methyldopa, propranolol and hydralazine therapy on cardiac adenylate cyclase activity in normal and spontaneously hypertensive rats

P. Robberecht, J. Christophe, P. Chatelain, 1981 .

Purification of a novel pancreatic secretory factor (PSF) and a novel peptide with VIP‐ and secretin‐like properties (helodermin) from Gila monster venom

P. Robberecht, A. Vandermeers, M. Vandermeers-piret, 1984, FEBS letters.

Pancreatic secretory factor (PSF), a protein from Gila monster venom stimulating enzyme secretion from rat pancreatic acini

P. Robberecht, A. Vandermeers, M. Vandermeers-piret, 1984, FEBS Letters.

Inhibitory effects of ATP and other nucleotides on atrial natriuretic peptide (ANP) binding to R1-type ANP receptors in human neuroblastoma NB-OK-1 cell membranes.

C. Delporte, J. Winand, M. Waelbroeck, 1992, Biochimica et biophysica acta.

Effects of a chemical sympathectomy on cardiac muscarinic receptors in normotensive (WKY) and spontaneously hypertensive (SHR) rats.

P. Robberecht, J. Christophe, P. Chatelain, 1983, Biochemical pharmacology.

Secretin Receptors in Human Pancreatic Membranes

L. Pradayrol, N. Vaysse, P. de Neef, 1988, Pancreas.

Properties of the VIP-PACAP type II receptor stably expressed in CHO cells

J. Vilardaga, P. Robberecht, A. Bollen, 1994, Regulatory Peptides.

Stimulation by inophore A23187 and carbamylcholine of prostaglandins release from the thyroid gland in vitro [proceedings].

J. Boeynaems, M. Waelbroeck, 1977, Archives internationales de physiologie et de biochimie.

Muscarinic receptor subtypes - search for selective agonists and antagonists

A. Leis, E. Mutschler, R. Tacke, 1996 .

The cardiac inotropic response to secretin is lower in genetically obese (fa/fa) than in lean (fa/?) Zucker rats

P. Robberecht, J. Christophe, J. Fontaine, 1983, Pflügers Archiv.

Characterization of secretin and vasoactive intestinal peptide receptors in rat pancreatic plasma membranes using the native peptides, secretin-(7-27) and five secretin analogues.

W. König, P. de Neef, P. Robberecht, 1982, Digestion.

VIP and related peptides induce rapid homologous desensitization in the human lymphoma SUP T1 cell line

P. Robberecht, J. Christophe, M. Waelbroeck, 1989, Peptides.

Topographical distribution of the secretin- and VIP-stimulated adenylate cyclase system in the heart of five animal species

P. Robberecht, J. Christophe, P. Chatelain, 1983, Pflügers Archiv.

The adenylate cyclase activity in heart membranes from normotensive and spontaneously hypertensive rats, after chemical sympathectomy, suggests the presence of presynaptic secretin receptors.

P. de Neef, P. Robberecht, J. Christophe, 1983, European journal of pharmacology.

Purification and sequence determination of a new muscarinic toxin (MT4) from the venom of the green mamba (Dendroaspis angusticeps).

A. Vandermeers, M. Vandermeers-piret, J. Rathé, 1995, Toxicon : official journal of the International Society on Toxinology.

Different antagonist binding properties of rat pancreatic and cardiac muscarinic receptors.

J. Christophe, J. Winand, M. Waelbroeck, 1987, Life sciences.

Mutational analysis of extracellular cysteine residues of rat secretin receptor shows that disulfide bridges are essential for receptor function.

J. Vilardaga, P. de Neef, P. Robberecht, 1997, European journal of biochemistry.

Different Domains of the VIP Receptors Modulate Agonist Affinity and Intrinsic Activity

P. Robberecht, M. Waelbroeck, M. Juarranz, 2000, Annals of the New York Academy of Sciences.

Characterization of a novel VPAC1 selective agonist and identification of the receptor domains implicated in the carboxyl‐terminal peptide recognition

C. Delporte, P. de Neef, P. Robberecht, 2000, British journal of pharmacology.

Lysine 173 residue within the first exoloop of rat secretin receptor is involved in carboxylate moiety recognition of Asp 3 in secretin.

J. Vilardaga, P. de Neef, P. Robberecht, 1996, Biochemical and biophysical research communications.

A new type of functional VIP receptor has an affinity for helodermin in human SUP‐T1 lymphoblasts

P. de Neef, P. Robberecht, J. Christophe, 1988, FEBS letters.

Biological recognition of enantiomeric silanes and Germanes: Syntheses and antimuscarinic properties of the enantiomers of the si/ge analogues cyclohexyl(hydroxymethyl)phenyl(2-piperidinoethyl)silane and -germane and their methiodides

E. Mutschler, R. Tacke, G. Lambrecht, 2008 .

Binding and functional properties of antimuscarinics of the hexocyclium/sila‐hexocyclium and hexahydro‐diphenidol/hexahydro‐sila‐diphenidol type to muscarinic receptor subtypes

J. Christophe, C. Strohmann, H. Zilch, 1989, British journal of pharmacology.

Biological recognition of enantiomeric silanes: Syntheses and antimuscarinic properties of optically active (2-aminoethyl)cyclohexyl(hydroxymethyl)phenylsilanes and related quaternary ammonium derivatives

E. Mutschler, R. Tacke, G. Lambrecht, 1995 .

Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction

M. Wuest, O. Hakenberg, U. Ravens, 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops

J. Steyaert, T. Laeremans, C. Blanchetot, 2016, mAbs.

Guanine nucleotide binding sites, responsible for adenylate cyclase activation and carbamylcholine binding inhibition, show similar properties in rat heart membranes.

P. Robberecht, J. Christophe, P. Chatelain, 1981, Journal of cyclic nucleotide research.

Effects of temperature and ethanol on agonist and antagonist binding to rat heart muscarinic receptors in the absence and presence of GTP.

P. de Neef, P. Robberecht, J. Christophe, 1985, The Biochemical journal.

Multiple effects of short-chain alcohols on binding to rat heart muscarinic receptors.

P. de Neef, P. Robberecht, J. Christophe, 1984, The Biochemical journal.

Stereoselectivity of (R)- and (S)-hexahydro-difenidol binding to neuroblastoma M1, cardiac M2, pancreatic M3, and striatum M4 muscarinic receptors.

J. Christophe, C. Strohmann, E. Mutschler, 1991, Chirality.

Binding of selective antagonists to four muscarinic receptors (M1 to M4) in rat forebrain.

J. Christophe, M. Waelbroeck, M. Tastenoy, 1990, Molecular pharmacology.

Rat cardiac muscarinic receptors. II. Influence of thyroid status and cardiac hypertrophy.

P. Robberecht, J. Christophe, P. Chatelain, 1982, Molecular pharmacology.

Thermodynamics of the interaction of insulin with its receptor.

E. Van Obberghen, P. De Meyts, M. Waelbroeck, 1979, The Journal of biological chemistry.

Importance of disulfide bonds in receptors for vasoactive intestinal peptide and secretin in rat pancreatic plasma membranes.

P. de Neef, P. Robberecht, J. Christophe, 1984, Biochimica et biophysica acta.

Decreased stimulation of adenylate cyclase by growth hormone-releasing factor in the anterior pituitary of old rats.

P. de Neef, P. Robberecht, J. Christophe, 1986, Neuroendocrinology.

Muscarinic receptor heterogeneity in rat central nervous system. I. Binding of four selective antagonists to three muscarinic receptor subclasses: a comparison with M2 cardiac muscarinic receptors of the C type.

P. Robberecht, J. Christophe, M. Gillard, 1987, Molecular pharmacology.

Stereoselectivity of the enantiomers of trihexyphenidyl and its methiodide at muscarinic receptor subtypes.

J. Christophe, E. Mutschler, U. Moser, 1988, European journal of pharmacology.

Secoverine is a non-selective muscarinic antagonist on rat heart and brain receptors.

J. Christophe, F. Brunner, M. Waelbroeck, 1986, European journal of pharmacology.

Inactivation of brain cortex muscarinic receptors by 4-diphenylacetoxy-1-(2-chloroethyl) piperidine mustard.

J. Christophe, R. Barlow, M. Waelbroeck, 1992, Biochemical pharmacology.

Binding properties of nine 4‐diphenyl‐acetoxy‐N‐methyl‐piperidine (4‐DAMP) analogues to M1, M2, M3 and putative M4 muscarinic receptor subtypes

J. Christophe, M. Waelbroeck, M. Tastenoy, 1992, British journal of pharmacology.

Binding affinities of hexahydro-difenidol and hexahydro-sila-difenidol analogues at four muscarinic receptor subtypes: constitutional and stereochemical aspects.

J. Christophe, C. Strohmann, E. Mutschler, 1991, European journal of pharmacology.

Stereoselectivity of procyclidine binding to muscarinic receptor subtypes M1, M2 and M4.

J. Christophe, E. Mutschler, R. Tacke, 1990, European journal of pharmacology.

Bretylium tosylate binds preferentially to muscarinic receptors labelled with [3H]oxotremorine M (SH or 'high affinity' receptors) in rat heart and brain cortex.

J. Christophe, M. Gillard, M. Svoboda, 1989, European journal of pharmacology.

Effects of d-tubocurarine on rat cardiac muscarinic receptors: a comparison with gallamine.

P. de Neef, P. Robberecht, J. Christophe, 1988, Journal of receptor research.

In vitro effects of gallamine on dissociation kinetics of (3H)N-methylscopolamine and (3H)pirenzepine from rat brain muscarinic receptors.

J. Christophe, M. Gillard, M. Waelbroeck, 1986, Journal of receptor research.

Inhibitory effects of quinidine on rat heart muscarinic receptors.

P. de Neef, P. Robberecht, J. Christophe, 1984, Life sciences.

Effects of verapamil on the binding properties of rat heart muscarinic receptors: evidence for an allosteric site.

P. de Neef, P. Robberecht, J. Christophe, 1984, Biochemical and biophysical research communications.

Selective labeling and localization of the M4 (m4) muscarinic receptor subtype.

D. Mash, D. Flynn, M. Waelbroeck, 1994, Molecular pharmacology.

Pharmacology of hexahydro-difenidol, hexahydro-sila-difenidol and related selective muscarinic antagonists.

C. Strohmann, R. Tacke, U. Moser, 1989, Trends in pharmacological sciences.

Stereoselectivity of the interaction of muscarinic antagonists with their receptors.

J. Christophe, C. Strohmann, E. Mutschler, 1989, Trends in pharmacological sciences.

Modulation byn-alkanols of rat cardiac adenylate cyclase activity

P. Robberecht, J. Christophe, P. Chatelain, 2005, The Journal of Membrane Biology.

G protein activation by G protein coupled receptors: ternary complex formation or catalyzed reaction?

D. Roberts, M. Waelbroeck, 2004, Biochemical pharmacology.

CCK and gastrin inhibit adenylate cyclase activity through a pertussis toxin‐sensitive mechanism in the tumoral rat pancreatic acinar cell line AR 4‐2J

L. Pradayrol, N. Vaysse, P. de Neef, 1988, FEBS letters.

Interaction of vasoactive intestinal peptide (VIP) and N-terminally modified VIP analogs with rat pancreatic, hepatic and pituitary membranes.

D. Coy, P. de Neef, P. Robberecht, 1986, European journal of biochemistry.

Heterogeneity of VIP-recogizing binding sites in rat tissues

S. Said, P. Robberecht, J. Christophe, 1982 .

[D-Phe4]peptide histidine-isoleucinamide ([D-Phe4]PHI), a highly selective vasoactive-intestinal-peptide (VIP) agonist, discriminates VIP-preferring from secretin-preferring receptors in rat pancreatic membranes.

D. Coy, P. de Neef, P. Robberecht, 1987, European journal of biochemistry.

Comparative structural requirements of thirty GRF analogs for interaction with GRF- and VIP receptors and coupling to adenylate cyclase in rat adenopituitary, liver and pancreas

D. Coy, P. Robberecht, J. Christophe, 1986, Peptides.

Specific labelling of high-affinity vasoactive intestinal peptide receptors in rat liver membranes by a growth hormone-releasing factor analog.

D. Coy, P. de Neef, P. Robberecht, 1986, Neuroendocrinology.

Comparative structural requirements of GRF analogs for occupancy of GRF and VIP receptors and coupling to adenylate cyclase in rat adenopituitary, liver and pancreas

D. Coy, P. Robberecht, J. Christophe, 1985, Regulatory Peptides.

Effects of HIS1 modifications on the ability of vasoactive intestinal peptide to stimulate adenylate cyclase from rat and human tissues

P. Robberecht, J. Christophe, M. Waelbroeck, 1984, Peptides.

Binding of vasoactive intestinal peptide and its stimulation of adenylate cyclase through two classes of receptors in rat liver membranes. Effects of 12 secretin analogues and 2 secretin fragments.

P. de Neef, P. Robberecht, J. Christophe, 1981, Biochimica et biophysica acta.

The pH dependence of insulin binding. A quantitative study.

M. Waelbroeck, 1982, The Journal of biological chemistry.

The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors

J. Vilardaga, P. Robberecht, A. Vandermeers, 1996, Peptides.

Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination.

J. Vilardaga, P. de Neef, P. Robberecht, 1995, Biochemical and biophysical research communications.

Molecular cloning and in vitro properties of the recombinant rabbit secretin receptor

C. Delporte, P. Robberecht, M. Svoboda, 1998, Peptides.

Activation of guanosine 5'-[gamma-(35)S]thio-triphosphate binding through M(1) muscarinic receptors in transfected Chinese hamster ovary cell membranes; 1. Mathematical analysis of catalytic G protein activation.

M. Waelbroeck, 2001, Molecular pharmacology.

Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors.

J. Christophe, C. Strohmann, E. Mutschler, 1992, European journal of pharmacology.

Pharmacological discrimination between enantiomeric germanes by muscarinic receptors: a study on germanium/silicon bioisosterism

E. Mutschler, R. Tacke, G. Lambrecht, 1996 .

Comparative efficacy of seven synthetic glucagon analogs, modified in position 1, 2 and/or 12, on liver and heart adenylate cyclase from rat

D. Coy, P. Robberecht, J. Christophe, 1986, Peptides.

Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes.

P. de Neef, P. Robberecht, M. Vandermeers-piret, 1998, European journal of pharmacology.

Comparison of VIP-secretin receptors in rat and human lung

P. Robberecht, M. Delhaye, J. Christophe, 1981, Peptides.

Identification of Key Residues for the Binding of Glucagon to the N-Terminal Domain of its Receptor: An Alanine Scan and Modeling Study

M. Prévost, P. Vertongen, M. Waelbroeck, 2012, Hormone and Metabolic Research.

Mutational and Cysteine Scanning Analysis of the Glucagon Receptor N-terminal Domain*

Martine Prévost, Vincent Raussens, M. Prévost, 2010, The Journal of Biological Chemistry.

Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligand's third residue.

F. Grégoire, P. Robberecht, P. Vertongen, 2002, The Biochemical journal.

Identification of secretin, vasoactive intestinal peptide and glucagon binding sites: from chimaeric receptors to point mutations.

P. Robberecht, P. Vertongen, J. Perret, 2001, Biochemical Society transactions.

Motilin and erythromycin-A share a common binding site in the third transmembrane segment of the motilin receptor.

I. Depoortere, T. Peeters, P. Robberecht, 2003, Biochemical pharmacology.

Motilin and erythromycin-A share a common binding site in the third transmembrane segment of the motilin receptor

I. Depoortere, T. Peeters, P. Robberecht, 2005 .

Lysine 195 and aspartate 196 in the first extracellular loop of the VPAC1 receptor are essential for high affinity binding of agonists but not of antagonists

P. Robberecht, P. Vertongen, I. Langer, 2003, Neuropharmacology.

A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.

P. Robberecht, P. Vertongen, I. Langer, 2002, Biochemical Society transactions.

Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.

P. de Neef, P. Robberecht, M. Vandermeers-piret, 1998, European journal of pharmacology.

A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.

P. Robberecht, P. Vertongen, I. Langer, 2002, Molecular endocrinology.

Inhibition of Forskolin‐stimulated cardiac adenylate cyclase activity by short‐chain alcohols

P. Robberecht, P. Chatelain, M. Waelbroeck, 1983, FEBS letters.

Vasoactive Intestinal Peptide Receptors in Pancreas and Liver. Structure‐Function Relationship a

P. Robberecht, J. Christophe, M. Svoboda, 1988, Annals of the New York Academy of Sciences.

Kinetic studies of [3H]-N-methylscopolamine binding to muscarinic receptors in the rat central nervous system: evidence for the existence of three classes of binding sites.

P. Robberecht, J. Christophe, M. Gillard, 1986, Molecular pharmacology.

Alterations of rat cardiac adenylate cyclase activity with age.

P. de Neef, P. Robberecht, J. Christophe, 1986, European journal of pharmacology.

Selective Alteration of Secretin-Stimulated Cardiac Adenylate Cyclase Activity in Streptozotocin-Diabetic Rats

L. Gillet, P. Robberecht, J. Christophe, 1983, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

The design and pharmacology of novel selective muscarinic agonists and antagonists.

U. Hacksell, U. Moser, G. Lambrecht, 1995, Life sciences.

Muscarinic receptor heterogeneity in rat central nervous system. II. Brain receptors labeled by [3H]oxotremorine-M correspond to heterogeneous M2 receptors with very high affinity for agonists.

J. Christophe, M. Gillard, M. Waelbroeck, 1987, Molecular pharmacology.

Contribution of the second transmembrane helix of the secretin receptor to the positioning of secretin

P. de Neef, P. Robberecht, A. Bollen, 1998, FEBS letters.

DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops

J. Steyaert, T. Laeremans, C. Blanchetot, 2016, mAbs.

Effect of freezing on the coupling of VIP receptors to adenylate cyclase in rat liver membranes.

P. Robberecht, M. Waelbroeck, P. Gourlet, 1988, Life sciences.

Effect of introduction of an arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors.

P. de Neef, P. Robberecht, A. Vandermeers, 1996, Biochimica et biophysica acta.

An alternative presentation of metabolism

M. Waelbroeck, 2007, Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology.

Transglutaminase-mediated polyamination of vasoactive intestinal peptide (VIP) Gln16 residue modulates VIP/PACAP receptor activity.

A. Facchiano, P. Stiuso, P. Robberecht, 2002, European journal of biochemistry.

Identification of drugs competing with d-tubocurarine for an allosteric site on cardiac muscarinic receptors.

M. Waelbroeck, 1994, Molecular pharmacology.